


GENT2

ONLINE TDM Gentamicin

cobas[®]**Order information**

REF		CONTENT		Analyzer(s) on which cobas c pack(s) can be used
04490843190	04490843500	ONLINE TDM Gentamicin (100 tests)	System-ID 07 6922 3	cobas c 311 , cobas c 501/502

Materials required (but not provided):

03375790190	Preciset TDM I CAL A-F (1 x 5 mL) Diluent (1 x 10 mL)	Codes 691-696		
04521536190	TDM Control Set Level I (2 x 5 mL) Level II (2 x 5 mL) Level III (2 x 5 mL)	Code 310 Code 311 Code 312		

English**System information**For **cobas c 311/501** analyzer:**GENT2:** ACN 416For **cobas c 502** analyzer:**GENT2:** ACN 8416**Intended use**In vitro test for the quantitative determination of gentamicin in serum and plasma on **cobas c** systems.**Summary**

Gentamicin measurements performed with this assay, in human serum and plasma, are used for monitoring gentamicin treatment to ensure appropriate therapy.

Gentamicin is an aminoglycoside antibiotic extracted from *Micromonospora purpurea* which is effective against a wide range of bacteria including most gram-negative bacteria and staphylococci. It is indicated in serious infections such as bacteraemia, urinary tract infections, chest infections, severe neonatal infections and other serious systemic infections due to susceptible organisms, in adults and children including neonates.^{1,2} The bactericidal action of gentamicin is due to its ability to bind the 30S subunit proteins of the bacterial ribosomes, thereby inhibiting protein synthesis and acting in both the proliferation and resting phases of bacteria.^{1,2,3}

The drug is mainly excreted by glomerular filtration and has a half life ranging from 2 to 3 hours.^{3,4} Overexposure to gentamicin has been associated with nephrotoxicity and ototoxicity, especially in patients with pre-existing renal damage, in pediatric, elderly and critically ill patients.^{4,5}

Therefore, serum concentration monitoring of gentamicin is recommended, especially in elderly, in newborns and in patients with impaired renal function in order to reduce the risk of serious complications and for adjustment of dosage administration as indicated.^{1,4,5,6,7,8,9,10}

Test principle

The assay is based on the kinetic interaction of microparticles in a solution (KIMS). Gentamicin antibody is covalently coupled to microparticles and the drug derivative is linked to a macromolecule. The kinetic interaction of microparticles in solutions is induced by binding of drug-conjugate to the antibody on the microparticles and is inhibited by the presence of gentamicin in the sample. A competitive reaction takes place between the drug conjugate and gentamicin in the serum sample for binding to the gentamicin antibody on the microparticles. The resulting kinetic interaction of microparticles is indirectly proportional to the amount of drug present in the sample.

Reagents - working solutions

- R1** Gentamicin conjugate; piperazine-N,N'-bis (ethanesulfonic acid) (PIPES) buffer, pH 7.2; preservative
- R2** Anti-gentamicin antibody (mouse monoclonal); latex microparticle; 3-(N-morpholino) propane sulfonic acid (MOPS) buffer, pH 7.5; stabilizer; preservative

R1 is in position B and R2 is in position C.

Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:

Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:

Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

Reagent handling

Ready for use

Carefully invert reagent container several times prior to use to ensure that the reagent components are mixed.

Storage and stability

Shelf life at 2-8 °C:

See expiration date on **cobas c** pack label

On-board in use and refrigerated on the analyzer:

12 weeks

Do not freeze.**Specimen collection and preparation**

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable.

Serum: Collect serum using standard sampling tubes.

Plasma: K₂- or K₃-EDTA, sodium citrate, or sodium, lithium, or ammonium heparin plasma.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Stability:

1 week capped at 2-8 °C

4 weeks capped at -20 °C (± 5 °C)

Freeze only once.

Centrifuge samples containing precipitates before performing the assay.

See the limitations and interferences section for details about possible sample interferences.

Specimens should not be repeatedly frozen and thawed.

Invert thawed specimens several times prior to testing.

Usual sampling time varies dependent upon desired measurement of peak or through values.¹¹

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

- See "Order information" section

- General laboratory equipment

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

Application for serum and plasma

Deselect Automatic Rerun for these applications in the Utility menu, Application screen, Range tab.

cobas c 311 test definition

Assay type	2-Point End		
Reaction time / Assay points	10 / 11-32		
Wavelength (sub/main)	800/600 nm		
Reaction direction	Increase		
Unit	µg/mL (µmol/L)		
Reagent pipetting		Diluent (H ₂ O)	
R1	100 µL	-	
R2	95 µL	-	
Sample volumes	Sample	Sample dilution	
		Sample	Diluent (H ₂ O)
Normal	2.0 µL	-	-
Decreased	2.0 µL	-	-
Increased	2.0 µL	-	-

cobas c 501/502 test definition

Assay type	2-Point End		
Reaction time / Assay points	10 / 18-49		
Wavelength (sub/main)	800/600 nm		
Reaction direction	Increase		
Unit	µg/mL (µmol/L)		
Reagent pipetting		Diluent (H ₂ O)	
R1	100 µL	-	
R2	95 µL	-	
Sample volumes	Sample	Sample dilution	
		Sample	Diluent (H ₂ O)
Normal	2.0 µL	-	-
Decreased	2.0 µL	-	-
Increased	2.0 µL	-	-

Calibration

Calibrators	S1-6: Preciset TDM I calibrators
Calibration mode	RCM
Calibration frequency	6-point calibration - after cobas c pack change - after reagent lot change - as required following quality control procedures

ACTION REQUIRED

After any calibration with Preciset TDM I Calibrators, the TDM Control Set have to be run in the order Level 3 to Level 1. Prior to running samples run

a blank serum sample. The blank serum sample can be scheduled for any R1/R2 assay.

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Traceability: This method has been standardized against USP reference standards. The calibrators are prepared to contain known quantities of gentamicin in normal human serum.

Quality control

For quality control, use control materials as listed in the "Order information" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

cobas c systems automatically calculate the analyte concentration of each sample.

Conversion factor:¹² µg/mL x 2.09 = µmol/L

Limitations - interference

Criterion: Recovery within ± 10 % of initial value at gentamicin levels of approximately 2 and 6 µg/mL (4.2 and 12.5 µmol/L).

Icterus:¹³ No significant interference up to an I index of 50 for conjugated and unconjugated bilirubin (approximate conjugated and unconjugated bilirubin concentration: 855 µmol/L or 50 mg/dL).

Hemolysis:¹³ No significant interference up to an H index of 1000 (approximate hemoglobin concentration: 621 µmol/L or 1000 mg/dL).

Lipemia (Intralipid):¹³ No significant interference up to an L index of 150. There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.

Triglycerides: No significant interference from triglycerides up to a concentration of 1000 mg/dL (11.3 mmol/L).

Rheumatoid factors: No significant interference from rheumatoid factors up to a concentration of 100 IU/mL.

Total protein: No significant interference from total protein up to a concentration of 12 g/dL.

Note

A negative bias of up to approximately 20 % has been observed with this assay for some samples artificially spiked with Gentamicin sulfate. Patient samples have been verified to recover correctly.

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.¹⁴

In very rare cases, patient samples may contain particle agglutinating proteins (e.g. heterophilic antibodies or antibodies due to abnormal immunoglobulin synthesis, such as gammopathies like MGUS^{b)} or Waldenström's macroglobulinemia), which may lead to incorrect low or high results with this assay. Correct results cannot be obtained by sample dilution and these samples should be analyzed by an alternative method.

b) Monoclonal Gammopathy of Unknown Significance

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

ACTION REQUIRED

Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on **cobas c** systems. The latest version of the carry-over evasion list can be found with the NaOH-SMS-SmpCln1+2-SCCS Method Sheets. For further instructions refer to the operator's manual. **cobas c 502** analyzer: All special wash programming necessary for avoiding carry-over is available via the **cobas** link, manual input is required in certain cases.

Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.

Limits and ranges**Measuring range**

GENT2

ONLINE TDM Gentamicin



Measuring range: 0.4-10.0 µg/mL (0.84-20.9 µmol/L)

Manually dilute samples having higher concentrations with Preciset TDM I diluent (0 µg/mL) (1 + 1) and reassay. Multiply the result by 2 to obtain the specimen value.

Lower limits of measurement

Lower detection limit of the test

0.3 µg/mL (0.63 µmol/L)

The lower detection limit represents the lowest measurable analyte level that can be distinguished from zero. It is calculated as the value lying 2 standard deviations above that of the 0 µg/mL calibrator (standard 1 + 2 SD, repeatability, n = 21).

Functional sensitivity

0.4 µg/mL (0.84 µmol/L)

The functional sensitivity is the lowest analyte concentration that can be reproducibly measured with a coefficient of variation of ≤ 20 % (repeatability, n = 21).

Expected values

Although optimum values may vary, peak serum values in the range of 6 to 10 µg/mL (12.5 to 20.9 µmol/L) and trough values in the range of 0.5 to 2.0 µg/mL (1.0 to 4.2 µmol/L) are generally accepted for therapeutic effectiveness.¹⁵ The achievement of non-toxic, but therapeutic, serum levels is often difficult, even in patients with normal renal function. Complications encountered with the use of gentamicin are ototoxicity and nephrotoxicity.^{16,17,18,19,20} However, these reactions are predictable, and close patient monitoring is essential for the successful use of this agent. The most serious toxic effect of gentamicin is permanent damage to the vestibular division of the eighth cranial nerve, which has been reported to occur most frequently in patients with renal failure. Since gentamicin is inherently unstable, is not metabolized and is excreted primarily by glomerular filtration, toxic concentrations of the drug may accumulate in the body when the dosage is not adjusted for patients with impaired renal function. While high serum levels can be toxic, indiscriminately low dosages of gentamicin will result in ineffective treatment for many strains of gram-negative bacteria. The indiscriminate use of low dosages of gentamicin may not only engender the emergence of gentamicin-resistant organisms, but also the emergence of aminoglycoside-resistant organisms.^{21,22,23} Current literature reflects increasing interest in once daily dosing versus the conventional administration of drug 2 to 4 times daily. Adoption of once daily dosing may require a revision of target peak and trough concentrations.^{24,25,26}

Expected values reflect the data and information provided in the reference and do not necessarily represent therapeutic recommendations and/or dosage instructions. For therapeutic recommendations and dosage instructions refer to applicable guidelines and the full prescription information of the drug.

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using human samples and controls in a modified NCCLS EP5-T2 protocol (repeatability n = 63, intermediate precision n = 63). The following results were obtained on the **cobas c 501** analyzer.

Repeatability	Mean		SD		CV
	µg/mL	µmol/L	µg/mL	µmol/L	%
Control 1	1.87	3.91	0.08	0.17	4.2
Control 2	4.37	9.13	0.08	0.17	1.8
Control 3	6.48	13.5	0.12	0.3	1.8
HS 1	1.90	3.97	0.07	0.15	3.6
HS 2	6.04	12.6	0.13	0.3	2.2

Intermediate precision	Mean		SD		CV
	µg/mL	µmol/L	µg/mL	µmol/L	%
Control 1	1.87	3.91	0.09	0.19	5.1
Control 2	4.37	9.13	0.09	0.19	2.0
Control 3	6.48	13.5	0.15	0.31	2.3
HS 1	1.90	3.97	0.08	0.17	4.1
HS 2	6.04	12.6	0.17	0.36	2.8

Intermediate precision	Mean		SD		CV
	µg/mL	µmol/L	µg/mL	µmol/L	%
Control 1	1.87	3.91	0.09	0.19	5.1
Control 2	4.37	9.13	0.09	0.19	2.0
Control 3	6.48	13.5	0.15	0.31	2.3
HS 1	1.90	3.97	0.08	0.17	4.1
HS 2	6.04	12.6	0.17	0.36	2.8

The data obtained on **cobas c 501** analyzer(s) are representative for **cobas c 311** analyzer(s).

Method comparison

Gentamicin values for human serum and plasma samples obtained on a **cobas c 501** analyzer (y) were compared with those determined using the corresponding reagent on a Roche/Hitachi 917 analyzer (x) and on a COBAS INTEGRA 800 analyzer (x).

Roche/Hitachi 917 analyzer

Sample size (n) = 64

Passing/Bablok²⁷

Linear regression

$y = 0.976x - 0.014 \mu\text{g/mL}$

$y = 0.976x - 0.016 \mu\text{g/mL}$

$r = 0.962$

$r = 0.999$

The sample concentrations were between 0.540 and 9.65 µg/mL (1.13 and 20.2 µmol/L).

COBAS INTEGRA 800 analyzer

Sample size (n) = 63

Passing/Bablok²⁷

Linear regression

$y = 0.983x - 0.214 \mu\text{g/mL}$

$y = 0.988x - 0.219 \mu\text{g/mL}$

$r = 0.965$

$r = 0.997$

The sample concentrations were between 0.530 and 9.14 µg/mL (1.11 and 19.1 µmol/L).

The data obtained on **cobas c 501** analyzer(s) are representative for **cobas c 311** analyzer(s).

Analytical specificity

The following compounds were tested for cross-reactivity.

Compound	Concentration Tested (µg/mL)	% Cross-Reactivity
Netilmicin	70	9.13
Sisomicin	131	8.16
Methotrexate	23	< 1.0
Tetracycline	40	< 1.0
Amikacin	250	< 0.1
Cephalexin	500	< 0.1
Chloramphenicol	300	< 0.1
Clindamycin	500	< 0.1
Kanamycin	250	< 0.1
Neomycin	100	< 0.1
Spectinomycin	200	< 0.1
Streptomycin	200	< 0.1
Tobramycin	100	< 0.1
Vancomycin	400	< 0.1
Amphotericin B	50	< 0.01
Ampicillin	78	< 0.01
Carbenicillin	500	< 0.01
Cephalosporin C	432	< 0.01
Cephalothin	63	< 0.01
Erythromycin	200	< 0.01

5-Fluorocytosine	700	< 0.01
Furosemide	100	< 0.01
Methylprednisolone	500	< 0.01
Oxytetracycline	37	< 0.01
Prednisolone	500	< 0.01

Tests were performed on 16 drugs. No significant interference with the assay was found.

Acetaminophen	Doxycycline (Tetracycline)
Acetyl cysteine	Ibuprofen
Acetylsalicylic acid	Levodopa
Ampicillin-Na	Methyldopa + 1.5 H ₂ O
Ascorbic acid	Metronidazole
Ca-Dobesilate	Phenylbutazone
Cefoxitin	Rifampicin
Cyclosporine	Theophylline

References

- Wockhardt UK Ltd. Gentamicin 40 mg/ml Solution for Injection or Infusion, gentamicin sulfate - Drug information [revised 2022 June; cited 2023 August 17]. Available from <https://www.medicines.org.uk/emc/product/2394/smpc>.
- Chen C, Chen Y, Wu P, et al. Update on new medical applications of gentamicin; evidence-based review. *J Formos Med Assoc* 2014 Feb;113(2):72-82.
- Milone MC, Shaw LM. Therapeutic Drugs and Their Management, In: Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, editors. *Tietz Textbook of Laboratory Medicine*, Saunders Elsevier, Philadelphia, 7th edition, 2023, chapter 42, p. 420-453.e9.
- Hodiamont CJ, van den Broek AK, de Vroom SL, et al. Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review. *Clin Pharmacokinet* 2022 Aug;61(8):1075-1094.
- Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. *Intensive Care Med* 2020 Jun;46(6):1127-1153.
- South Australian expert Advisory Group on Antimicrobial Resistance (SAAGAR). Aminoglycosides: Recommendations for use, dosing and monitoring. Clinical Guideline No.: CG088 [Version No.: 3.0. Approval date: 11th December 2020]. Available from: https://www.sahealth.sa.gov.au/wps/wcm/connect/e4c8cb004877c5c3a295f67675638bd8/Aminoglycosides_01062017.pdf?MOD=AJPERES.
- The National Institute for Health and Care Excellence (NICE) (2021) Neonatal infection: antibiotics for prevention and treatment (NICE Guideline [NG195]) [revised 2022 September; cited 2023 August 17]. Available from: <https://www.nice.org.uk/guidance/ng195>.
- Fonzo-Christe C, Guignard B, Zaugg C, et al. Impact of clinical decision support guidelines on therapeutic drug monitoring of gentamicin in newborns. *Ther Drug Monit* 2014 Oct;36(5):656-662.
- Hollander EM, van Tuinen EL, Schölvinck EH, et al. Evaluation of Dosing Guidelines for Gentamicin in Neonates and Children. *Antibiotics (Basel)* 2023 April 25;12(5):810.
- Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC Guidelines for the management of endocarditis. *Eur Heart J* 2023 Aug 25;ehad193.
- O'Bey KA, Jim LK, Gee JP, et al. Temperature dependence of the stability of tobramycin mixed with penicillins in human serum. *Am J Hosp Pharm* 1982;39(6):1005-1008.
- Tietz NW. *Fundamentals of Clinical Chemistry*. 3rd ed. Philadelphia, PA: WB Saunders Co 1995:834.
- Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. *Clin Chem* 1986;32:470-475.
- Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. *Clin Chem Lab Med* 2007;45(9):1240-1243.
- Taylor WJ, Diers-Caviness MH (eds.). *A Textbook for the Clinical Application of Therapeutic Drug Monitoring*. Abbott Laboratories 1986:296.
- Cox CE. Gentamicin. *Med Clin North Am* 1970;54:1305-1315.
- Jackson GG, Arcieri GM. Ototoxicity of gentamicin in man: a survey and controlled analysis of clinical experience in the United States. *J Infect Dis* 1971;124(Suppl):130-137.
- Arcieri GM, Falco FG, Smith HM, et al. Clinical research experience with gentamicin. Incidence of adverse reactions. *Med J Aust* 1970;1(Suppl):30-34.
- Falco FG, Smith HM, Arcieri GM. Nephrotoxicity of aminoglycosides and gentamicin. *J Infect Dis* 1969;119(4):406-409.
- Gyselync AM, Forrey A, Cutler R. Pharmacokinetics of gentamicin: distribution and plasma and renal clearance. *J Infect Dis* 1971;124(Suppl):70-76.
- Riff LJ, Jackson GG. Pharmacology of gentamicin in man. *J Infect Dis* 1971;124(Suppl):98-105.
- Weinstein MJ, Drube CG, Moss EL Jr, et al. Microbiologic studies related to bacterial resistance to gentamicin. *J Infect Dis* 1971;124(Suppl):11-17.
- Jackson GG, Riff LJ. Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin. *J Infect Dis* 1971;124(Suppl):185-191.
- Barclay ML, Begg EJ, Hickling KG. What is the evidence for once-daily aminoglycoside therapy? *Clin Pharmacokinet* 1994;27(1):32-48.
- Hustinx WN, Hoepelman IM. Aminoglycoside dosage regimens. Is once a day enough? *Clin Pharmacokinet* 1993;25(6):427-432.
- Bertino JS Jr, Rodvold KA, Destache CJ. Cost considerations in therapeutic drug monitoring of aminoglycosides. *Clin Pharmacokinet* 1994;26(1):71-81.
- Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. *J Clin Chem Clin Biochem* 1988 Nov;26(11):783-790.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

The Summary of Safety & Performance Report can be found here: <https://ec.europa.eu/tools/eudamed>

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see navifyportal.roche.com for definition of symbols used):

CONTENT

Contents of kit



Volume for reconstitution

GTIN

Global Trade Item Number

Rx only

For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.

COBAS, NAVIFY, ONLINE TDM and PRECISET are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2023, Roche Diagnostics

04490843500V15.0

GENT2

ONLINE TDM Gentamicin

cobas®

CE 0123



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

+800 5505 6606

